Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of FMX103 in Papulopustular Rosacea
NCT03276936Phase 3Completed
- Sponsor
- Vyne Therapeutics
- Start
- Sep 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of minocycline in papulopustular rosacea, sponsored by Vyne Therapeutics. Started Sep 2017; status: completed.
02
Drugs
minocycline
03
Conditions
papulopustular rosacea
Beyond the preview
Go deeper on NCT03276936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03276936.